StockData

Abundia Global Impact vs Arcadia Biosciences

AGIG and RKDA side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How AGIG and RKDA compare

Abundia Global Impact is the larger company, worth 61 times as much as Arcadia Biosciences ($27.8M against $457K).

Abundia Global Impact grew revenue faster over the last twelve months (180% versus −12.2% for Arcadia Biosciences).

Arcadia Biosciences keeps more of each dollar of sales as profit, with a net margin of −235% compared with −1456% at Abundia Global Impact.

Arcadia Biosciences scores higher on the StockData Score (6 against 2 for Abundia Global Impact), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricAGIGRKDA
Size and price
Market cap$27.8M$457K
Share price$0.630$0.190
Change, 1 year−88.2%−95.0%
Change, 5 years−96.3%−99.7%
Beta (5Y)−0.061.72
Employees28
StockData Score
Total score26 (better)
Valuation score01 (better)
Growth score1 (better)0
Performance score1 (better)0
Health score05 (better)
Dividend score00
Valuation
P/S11.2×0.1× (better)
Growth
Revenue growth (TTM)180% (better)−12.2%
Revenue growth, 5Y average−5.8% (better)−9.6%
Profitability
Gross margin–34.6%
Operating margin−1397%−80.1% (better)
Net margin−1456%−235% (better)
Return on equity−428%–
Return on invested capital−1870%–
Financial health
Interest coverage−154.4×–
Current ratio0.593.49 (better)
Altman Z-score−3.30 (better)−69.78
Piotroski F-score4 (better)3
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions5.9%8.8%
Held by insiders73.0%1.4%
Insider net buying, 12 months$276K–
Short interest, % of float2.9%4.9%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.